Intellipharmaceutics International Probability of Future OTC Stock Price Finishing Over 0.0
Intellipharmaceutics' future price is the expected price of Intellipharmaceutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Intellipharmaceutics International performance during a given time horizon utilizing its historical volatility. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Please specify Intellipharmaceutics' target price for which you would like Intellipharmaceutics odds to be computed.
Intellipharmaceutics |
Intellipharmaceutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Intellipharmaceutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Intellipharmaceutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Intellipharmaceutics is not yet fully synchronised with the market data | |
| Intellipharmaceutics has some characteristics of a very speculative penny stock | |
| Intellipharmaceutics has a very high chance of going through financial distress in the upcoming years | |
| Intellipharmaceutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Intellipharmaceutics International has accumulated 2.01 M in total debt with debt to equity ratio (D/E) of 165.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intellipharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Intellipharmaceutics until it has trouble settling it off, either with new capital or with free cash flow. So, Intellipharmaceutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intellipharmaceutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intellipharmaceutics to invest in growth at high rates of return. When we think about Intellipharmaceutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 1.4 M. | |
| Intellipharmaceutics International has accumulated about 79.65 K in cash with (2.46 M) of positive cash flow from operations. |
Intellipharmaceutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Intellipharmaceutics OTC Stock often depends not only on the future outlook of the current and potential Intellipharmaceutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Intellipharmaceutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.1 M |
Intellipharmaceutics Technical Analysis
Intellipharmaceutics' future price can be derived by breaking down and analyzing its technical indicators over time. Intellipharmaceutics OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Intellipharmaceutics International. In general, you should focus on analyzing Intellipharmaceutics OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Intellipharmaceutics Predictive Forecast Models
Intellipharmaceutics' time-series forecasting models is one of many Intellipharmaceutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Intellipharmaceutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Intellipharmaceutics
Checking the ongoing alerts about Intellipharmaceutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Intellipharmaceutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Intellipharmaceutics is not yet fully synchronised with the market data | |
| Intellipharmaceutics has some characteristics of a very speculative penny stock | |
| Intellipharmaceutics has a very high chance of going through financial distress in the upcoming years | |
| Intellipharmaceutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Intellipharmaceutics International has accumulated 2.01 M in total debt with debt to equity ratio (D/E) of 165.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intellipharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Intellipharmaceutics until it has trouble settling it off, either with new capital or with free cash flow. So, Intellipharmaceutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intellipharmaceutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intellipharmaceutics to invest in growth at high rates of return. When we think about Intellipharmaceutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 1.4 M. | |
| Intellipharmaceutics International has accumulated about 79.65 K in cash with (2.46 M) of positive cash flow from operations. |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world |